Diagonal Bio (DIABIO) Q4 2024 earnings summary

Executive summary

• Net sales for 2024 reached 62 KSEK, up from 23 KSEK year-over-year, with capitalised development at 1,063 KSEK and other operating income at 6 KSEK.

• Operating loss for 2024 was -9,930 KSEK, an improvement from -11,678 KSEK in 2023.

• Cash flow for the year was -2,154 KSEK, with cash and cash equivalents at year-end totaling 818 KSEK.

• Strategic partnerships and pilot tests for LAMPlifyⓇ expanded, including successful external validation and first sales.

• Rights issue in early 2025 was oversubscribed, raising approximately SEK 7.7 million before costs.

Financial highlights

• Net sales for Q4 2024 were 62 KSEK, compared to 23 KSEK in Q4 2023.

• Operating loss in Q4 2024 was -2,260 KSEK, compared to -2,530 KSEK in Q4 2023.

• Cash flow in Q4 2024 was -911 KSEK, with year-end cash at 818 KSEK.

• Investments in intangible assets during Q4 2024 totaled 48 KSEK.

• Weighted average shares during 2024 were 400,714,213.

Outlook and guidance

• Focus remains on commercializing LAMPlifyⓇ and expanding into veterinary, equine, and agricultural diagnostics.

• Continued efforts to secure long-term financing and strategic partnerships.

• Ongoing expansion of product validation and market reach, including new pilot programs and orders.